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ABSTRACT
Diabetic enteropathy is a specific diabetic complica-
tion. It could be presented as constipations, diarrhoea 
or faecal incontinence. The aetiology is multifactorial. 
The main role is attributed to irreversible autonomic 
neuropathy, which often coexists with peripheral sen-
sorimotor neuropathy. Nowadays, enteropathy is diag-
nosed after exclusion of other causes, like coeliac dis-
ease, hypo- or hyperthyroidism, inflammatory bowel 
disease, small intestinal bacterial overgrowth, exocrine 
pancreatic insufficiency and adverse drug reaction. 
The article presents new reports about enteropathy 
reversibility after simultaneous pancreas-kidney trans-
plantation in patients with abnormal levels of IGF-1 
and IGFBP3. It provides new data on pathogenesis of 
enteropathy and presents new diagnostic and thera-
peutic approaches. (Clin Diabetol 2017; 6, 3: 105–110)
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Introduction
Diabetes is a complex disease, requiring an in-
terdisciplinary approach. It seems obvious that the 
diabetes care team should include an ophthalmologist, 
nephrologist, cardiologist and podiatrist. While it is 
well-known how to diagnose retinopathy, nephropa-
thy or peripheral neuropathy, therapeutic options for 
entero pathy induced by diabetes include only sympto-
matic treatment. Diabetic enteropathy, also referred to 
as diabetic visceropathy, is a real problem for patients, 
resulting in significant decrease in the quality of life.
Symptomatology
Diabetic enteropathy may manifest as constipation, 
diarrhoea and faecal incontinence. Statistically, most 
frequent symptom is constipation, occurring in nearly 
20% of patients [1] (Tab. 1). Another common symptom 
is diarrhoea, which may be constant or periodic. The 
latter form may alternate with constipation or a normal 
rhythm of defecation. Most patients report symptoms 
occurring during the day, but some also experience 
night-time symptoms [1, 2]. Among patients with 
diarrhoea, about 60% have diabetes-related diarrhoea 
[3]. Faecal incontinence, isolated or accompanying 
diarrhoea, is undoubtedly a symptom that significantly 
impairs the quality of life. It is the second most frequent 
symptom of enteropathy. In most cases, it is associated 
with loose stools, which is an additional factor impair-
ing the mechanism of normal bowel control [4].
Pathogenesis of enteropathy
Neuropathic theory
The aetiology of enteropathy is multifactorial and 
remains unexplained. Currently, the main role is at-
tributed to irreversible diabetic autonomic neuropathy 
(DAN), which significantly disturbs regulation of the 
enteric autonomic system activity and, therefore, in-
testinal motor activity and function [1]. It is caused, 
among other factors, by hyperglycaemia-induced 
microangiopathy (Fig. 1) [5]. It results from damage 
caused by:
 — reactive oxygen species (ROS) [6, 7];
 — advanced glycation end-products (AGE) [7]; 
excessive activation of the polyol pathway, which 
promotes glucose transformation to sorbitol, and 
thereby contributes to changed nerve excitability 
and increased oxidative stress [7];
Table 1. Prevalence of symptoms of diabetic enteropathy
Symptom Prevalence in diabetic patients
Constipation 18% [1]
Diarrhoea 9% [1]
Faecal incontinence 12% [4]
Clinical Diabetology 2017, Vol. 6, No. 3
106
 — activation of diacylglycerol and protein kinase C 
pathway, which contributes to the overproduction 
of proinflammatory mediators such as PG2 [8].
The neuropathic theory is confirmed by the fact 
that gastrointestinal symptoms in diabetic patients 
correlate with peripheral neuropathy [9]. Moreover, 
an important factor that should not be forgotten is 
the effect of symptomatic atherosclerosis of visceral 
vessels on the development of diabetic microangio-
pathy.
Insulin-like growth factor-dependent theory
D’Addio et al. shed new light on the problem of 
enteropathy, demonstrating new pathomechanisms, 
and arguing, contrary to previous hypotheses, that it 
can be reversible [10]. Researchers have shown that 
the serum level of an IGF-1 binding protein (IGFBP3) 
produced in the liver in type 1 diabetic patients with 
the symptoms of enteropathy was almost 5 times 
higher than in healthy subjects. Hepatocytes of these 
patients exhibit higher expression of IGFBP3 in immu-
nohistochemistry. Moreover, IGF-1 concentrations are 
significantly reduced. The TMEM219 receptor has been 
identified in intestinal crypts. Under deficiency of IGF-1 
and excess of IGFBP3, this receptor activates the caspase 
pathway, thereby leading to impaired differentiation 
of colonic stem cells (CoSC) (Fig. 2).
Histopathological examinations of intestinal mu-
cosa of patients with enteropathy show a number of 
abnormalities compared to healthy individuals. In pa-
tients with enteropathy, the number of intestinal crypts 
is markedly reduced and they are characterized by the 
presence of structural abnormalities and hardening of 
the lamina propria of intestinal mucosa (Fig. 3). There 
was also a reduction in intestinal epithelial cell prolifera-
tion, signs of nerve degeneration, and reduced expres-
sion of serotonin in intestinal neuroendocrine cells.
It has been demonstrated in cell culture of CoSCs 
from healthy individuals that isolated hyperglycaemia 
does not lead to direct epithelial injury, whereas the 
addition of serum from patients with enteropathy 
results in characteristic damage. Addition of exces-
sive amount of IGFBP3 to healthy-cell culture inhibits 
cell proliferation even in the presence of IGF-1, but 
Figure 1. Pathogenesis of autonomic neuropathy — modified from [24]. AGE — advanced glycation end-products; NO — nitric oxide
Figure 2. Mechanism of destructive action of IGFBP3 on colo-
nic crypt stem cells IGFBP3 by binding to its receptor TMEM219 
on colonic stem cell membrane suppresses proliferation and 
differentiation of these cells and activates apoptotic path-
way. IGFBP3 — insulin-like growth factor binding protein 3; 
IGF-1 — insulin-like growth factor 1; CoSC — colonic stem 
cell; TMEM219 — transmembrane protein 219 also known 
as IGFBP3 receptor
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this phenomenon is completely reversible after the 
addition of a caspase inhibitor. It seems therefore that 
IGFBP3 is a key factor responsible for the pathogenesis 
of the observed phenomenon and that by acting via the 
TMEM219 receptor this protein activates the apoptosis 
pathway independently of IGF-1. The authors are cur-
rently investigating the monoclonal antibody that blocks 
the TMEM219 receptor and the results are promising.
Some patients who participated in the study 
underwent simultaneous kidney and pancreas trans-
plantation. During the 8-year follow-up, these patients 
showed significant improvement in microscopic intes-
tinal morphology, normalization of blood IGF-1 and 
IGFB3 levels, and clinical improvement. Moreover, they 
were complete independent from exogenous insulin. 
This experiment fundamentally contradicts the irrevers-
ibility of enteropathy. It also allows for the conclusion 
indicating not only of the complexity of pathogenesis 
of the disease, but also the need to revise existing find-
ings. Perhaps there are at least two forms of diabetic 
enteropathy: neuropathic and IGF-dependent. IGF-
-dependent theory is new one and certainly requires 
further research, but for the first time in the long while 
it gives hope extensive understanding of the source of 
the problem.
Abnormalities of migrating myoelectric 
complex in enteropathy
Visceropathy is associated with dysfunction of 
the enteric nervous system (ENS), which is a division 
of autonomic nervous system. Its main components 
are myenteric (Auerbach) and submucosal (Meissner) 
plexuses. This system is partly controlled by the central 
nervous system and partly acts independently via reflex 
activity [11].
Under normal conditions, the electrical activity of 
intestinal smooth muscles consists of slow waves, also 
known as the basal electrical rhythm (BER), and action 
potentials. Slow waves do not reach the threshold poten-
tial, so they do not cause intestinal muscle contraction, 
but they are very important because action potential can 
only arise at the peak of depolarization. The resulting po-
tential propagates to the surrounding cells through low-
resistance junction, causing muscle contraction [2, 11].
During the interdigestive period, a variable cyclic 
electrical activity called the migratory myoelectric 
complex (MMC) is recorded in the smooth muscles 
of the intestine. It arises mainly in the stomach. One 
MMC cycle consists of four phases and lasts about 
90–120 minutes. In the first phase only slow waves are 
observed, thus there is no systolic action. At the second 
phase, individual action potentials appear, causing only 
moderate muscle contractions. Then, in the third phase, 
which lasts only 4–8 minutes, burst of action potential 
occur at the peak of the slow waves, which determines 
intensive intestinal motility. Phase four is the transition 
phase before a new cycle [2, 11].
Dooley et al. have determined that intestinal pas-
sage in patients with diabetes, autonomic neuropathy 
and unexplained diarrhoea is disturbed, and that this 
Figure 3A. Intestinal mucosa of a healthy person; B. Intestinal mucosa of a patient with diabetic enteropathy; 1 — reduced 
number of intestinal crypts; 2 — abnormal morphology of intestinal crypts; CoSC — colonic stem cell
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disturbance involves many MMC abnormalities. Most 
of MMC cycles had no antral component, and in the 
remaining phase III was absent or started in the small 
intestine omitting the stomach and duodenum [12]. In 
25% of patients participating in the study by Dooley 
small intestinal bacterial overgrowth (SIBO) was diag-
nosed based on the hydrogen breath test and clinical 
improvement was obtained after antibiotic therapy. 
Although autonomic neuropathy may theoretically 
promote the occurrence of SIBO in diabetic patients 
by disturbing the intestinal passage, diabetes itself 
seems to have protective effect. In a study conducted 
at the Department of Internal Medicine and Diabeto-
logy at the Medical University of Poznan, patients with 
diabetes were almost two-fold more likely to have SIBO 
compared to a control group consisting of healthy and 
asymptomatic volunteers (41 vs. 75%). However, the 
prevalence of autonomic neuropathy in the study group 
was not high (14.5%) [13].
Defaecation reflex disorders  
in diabetic enteropathy
Changes occurring in the course of enteropathy lead 
also to impairment of defaecation reflex, which may 
manifest as a faecal incontinence. Under normal condi-
tions, mechanoreceptors are stimulated in response to 
stretching the walls of the rectal bubble. As a result of 
the intramural and spinal reflexes (defaecation centre 
in the sacral spinal cord), the external anal sphincter 
is relaxed, the levator and muscle is contracted, and 
in conjunction with the intra-abdominal pressure, the 
faeces is excreted. A healthy person can voluntary stop 
this process by tightening external anal sphincter [11].
Aitchison et al. addressed the problem of faecal 
incontinence in people with diabetes with reference 
to pathophysiological aspects. Their study showed 
that patients with diabetes-related faecal incontinence 
showed decreased rectal and anal canal pressures, 
elevated rectal filling threshold, delayed external anal 
sphincter response, disturbed anal reflex (contraction 
of the external anal sphincter in response to irritation 
of the anal area) compared with diabetic patients with 
normal faecal continence and healthy volunteers [14].
Diagnostics
Diagnosis of enteropathy is even more complex 
than its pathogenesis. This is a diagnosis of exclusion. 
Despite the often obvious clinical symptoms and our 
conviction concerning the presence of this complica-
tion, we are obliged to carry out thorough differential 
diagnosis. Depending on the dominant symptom, such 
conditions as coeliac disease, thyroid dysfunction, in-
flammatory bowel disease, SIBO, exocrine pancreatic 
insufficiency, and finally the effects of the medications, 
should be taken into account [2]. Among them, the 
most common cause of chronic diarrhoea is metformin 
[3]. Attention should also be paid to the possibility of 
additional involvement of atherosclerosis in the devel-
opment of visceropathy.
In most cases, endoscopy of upper and lower 
gastrointestinal tract and TSH level measurement are 
considered a primary examination. Coeliac disease can 
be excluded based on histopathological examination 
of the duodenal biopsy specimen obtained during 
gastroduodenoscopy along with anti-EmA (anti-
endomysium) and anti-tTG (anti-transgelatinase) IgA- 
-class antibody titres determination, taking into ac-
count possible IgA deficiency. Exceptionally, the diagno-
sis can be made without biopsy based on characteristic 
symptoms, anti-tTG antibody level 10-fold higher than 
ULN, and positive results for HLA-DQ2 or HLA-DQ8 [15]. 
In SIBO diagnostics, the use of hydrogen breathing test 
is increasingly popular; however, in case of its limited 
availability, empirical antibiotic therapy and clinical 
observation are acceptable [2]. It may also be useful 
to test a stool sample for parasites.
Anorectal manometry is a valuable test in patients 
with faeces incontinence. It allows objectification of the 
problem and may be the first step towards providing a 
patient with a treatment. Symptomatic patients with 
diabetes have demonstrated an elevated threshold for 
the reception of sensory signals from the upper anal 
canal, which may be associated with delated perception 
of a need to defecate [14].
The optimal solution would be finding a single 
test or biomarker allowing the diagnosis to be quickly 
established without burdening the patient with nu-
merous examinations. The search is still ongoing. One 
of the proposals is to test the length of the intestinal 
passage by scintigraphy performed after a standardized 
meal consisting of isotope-labelled eggs. Diagnosis of 
delayed passage through the small intestine may be 
established when after 6 hours < 40% of the total 
isotope activity in the small intestine accumulates in 
the ileocoecal region. In order to evaluate the passage 
through the large intestine, the acquisition is performed 
additionally at 24, 48 and 72 hours [16]. However, this 
method is cumbersome, long-lasting, expensive and 
associated with exposition to radiation and therefore 
is not widely used in diagnostics. An interesting, but 
expensive, alternative is the use of the wireless motility 
capsule (WMC), which is sensitive to pH and pressure 
changes in the gastrointestinal tract, and is therefore 
able to recognize when the environment changes from 
the small intestine to the large intestine [17]. The de-
scribed methods are interesting from a research point 
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of view, but for the clinician they do not provide much 
information, because it is still necessary to exclude 
the causes of the altered passage other than diabetic 
enteropathy. 
In conclusion, painstaking differential diagnosis 
remains the standard for the management of patients 
with the suspicion of diabetic enteropathy. This not only 
contributes to the delay in diagnosis, but also to the 
statistical underestimation of the scale of the problem.
Treatment
Due to unclear pathogenesis and lack of causative 
treatment, only symptomatic treatment is available for 
patients with visceropathy (Tab. 2).
Antidiarrhoeal medications, such as loperamide 
or atropine/diphenoxylate, are commonly used in the 
therapy of diarrhoea [2, 18]. Empirical antibiotic therapy 
(e.g. rifaximin) is also permissible, if SIBO is suspected [2].
A key treatment for constipation is lifestyle modi-
fication involving proper hydration, high-fibre diet and 
physical exercise. Adjunctive treatment may include 
pharmacological agents, such as lactulose and macro-
gol. If these drugs are ineffective, the use of a prokinetic 
agent such as cisapride or a newly introduced 5-HT4 
receptor agonists, prucalopride, should be considered 
[18]. Reports from a study on cholinesterase inhibitor in 
the form of orally administered pyridostigmine indicate 
that in patients with diabetic autonomic neuropathy it 
accelerates the passage through the colon, affecting 
the frequency of bowel movements and stool consist-
ency, and facilitating defaecation [19].
Faecal incontinence is the most difficult symptom 
to treat. Subsidence of diarrhoea alone may result in 
improvement in most patients. In refractory cases, 
patients may benefit from biofeedback therapy, i.e. 
behavioural training. Biofeedback effectively eliminates 
or significantly reduces the incidence of faecal incon-
tinence in diabetic patients [20]. The patient performs 
anal sphincter muscle exercises at home, several times 
a day for 15 minutes (see Figure 4). The first effects can 
be seen after several months of regular exercise. The 
electrode located in the anal canal records the electrical 
activity of the anal sphincter complex during contrac-
tion. The device informs the patient if the exercise was 
perform correctly. Patients with sensory impairment 
are provided with an additional exercise program with 
a balloon filled with gradually increasing volume, so 
that the patient tightens the anal sphincter at the right 
time. This leads to a reflex mechanism [21]. The next 
step may be the use of transrectal electrostimulation, 
where the rectal electrode stimulates the sphincters 
with appropriate electric stimulus [22].
There were also attempts to treat faecal inconti-
nence surgically by implanting magnetic anal sphincter 
device [23]. As previously mentioned, D’Addio et al. 
have reported promising results of their current studies 
on anti-TMEM219 monoclonal antibody (IGFBP3 recep-
tor present in intestinal crypts), both in in vitro and in 
vivo and in a mouse model [10]. This gives hope for 
effective causal treatment in the future and can be a 
great alternative to symptomatic treatment that often 
remains ineffective.
Table 2. Pharmacological therapy in symptomatic treat-
ment of diabetic enteropathy
Symptom Medication
Diarrhoea Loperamide
Diphenoxylate and atropine
Rifaximin
Amoxicillin and clavulanic acid
Ciprofloxacin
Metronidazole
Doxycycline
Constipation Lifestyle modification
Lactulose
Macrogol
Cisapride 
Prucalopride 
Pyridostigmine
Faecal incontinence Antidiarhoeal treatment (see above)
Biofeedback Figure 4. Electrostimulator with a rectal electrode used in 
biofeedback therapy for faecal incontinence
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Summary
Diabetic enteropathy is an important clinical 
problem that must be addressed by a doctor who 
treats a diabetic patient. However, despite complex 
aetiopathogenesis, complicated diagnosis and lack of 
causative treatment, we are not completely helpless. 
Recent hypotheses, competing with the neuropathic 
theory of atrophic visceropathy, such as the destruc-
tive effect of IGFBP3 on the morphology of intestinal 
crypts, shed a new light on its genesis. Studies on the 
role of IGFBP3 and anti-TMEM219 antibodies against 
the IGFBP3 receptor give hope for the development of 
effective causative therapy and thus improvement of 
the quality of life. In addition, blood serum IGFBP3 can 
be a biomarker to significantly improve the diagnosis 
of diabetic enteropathy. It should be emphasized, how-
ever, that recent reports require further investigation 
before we can use them in clinical practice.
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